Text
Berbagai Keluhan Fisik yang Dialami Pasien Osteoartritis Akibat Terapi Natrium Diklofenak Dibandingkan Kurkuminoid Ekstrak Rimpang Kunyit
Background: The prevalence of osteoarthritis (OA) in the community is high and this disease is the second largest cause of physical disability in the world. Degeneration and joint inflammation occurred in OA. Curcuminoid is a secondary metabolite present in the rhyzome of turmeric and ginger. Curcuminoid could be used to treat rheumatic diseases. Diclofenac sodium is able to inhibite the production of prostaglandin-E2 (PG-E2) by inhibition the cycloxygenase-2 (COX-2) activity. On the other hand diclofenac sodium also inhibite the physiologic enzyme cycloxygenase-l (COX-I) activity, this inhibition may produce some complaints to the patients since the COX-l is important in body equilibrium. Objective: To assess some complaints of patients with osteoarthritis in treatment using curcuminoid from Curcuma domestica Val. rhyzome extract compared to diclofenac sodium. Method: This study was conducted with the prospective randomized open end blinded evaluation (PROBE) design. A total of 80 patients with knee osteoarthritis were included in this study (39 patients received 3x30 mg daily of curcuminoid from Curcuma domestica Val. rhyzome extract for 28 days treatment and 41 patients received 3x25 mg daily of diclofenac sodium for 28 days). The number needed to harm analysis was conducted in comparing the symptoms of head, chest, gastrointestinal and urinary tract complaints. Results: The number needed to harm (NNH) for headache was 500, palpitation was 42, shortness of breath was 42, nausea was 21, diarrhea was 42 and micturition complaints was 500. Conclusion: Although the number of patient who have chest and gastrointestinal complaints was higher in using diclofenac sodium, but no statistically significant difference either of head, chest, gastrointestinal and urinary tract complaints between the curcuminoid and diclofenac sodium treatment groups.
No other version available